Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Hematology"
DOI: 10.1007/s00277-025-06221-4
Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive and rare hematologic malignancy characterized by poor response to multiagent chemotherapy and dismal survival outcomes of 8–16 months. Tagraxofusp, the first-in-class CD123-directed antineoplastic agent, has… read more here.
Keywords: cell neoplasm; versus tagraxofusp; ven hma; dendritic cell ... See more keywords
Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-197933
Abstract: Background Acute myeloid leukemia with myelodysplasia-related changes (AML-MR) encompasses AML with myelodysplasia-related gene mutations and cytogenetic abnormalities in the International Consensus Classification (ICC). Patients with some MR mutations have been shown to benefit from venetoclax… read more here.
Keywords: cohort; aml patients; ven hma; rate ... See more keywords
Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202500
Abstract: Background Acute myeloid leukemia with myelodysplasia related (AML-MR) represents a high-risk and heterogeneous subtype of AML, with a lower remission rates and median overall survival compared to non-MR AML. Given that AML-MR tends to occur… read more here.
Keywords: priming regimens; ven hma; compared priming; group ... See more keywords
Real-World Experience with Generic Venetoclax Plus Hypomethylating Agent Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia Patients in Resource-Limited Setting: A Single-Center Study from India
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-210666
Abstract: INTRODUCTION The standard induction therapy for acute myeloid leukemia (AML) is the intensive 3+7 regimen. However, a significant proportion of newly diagnosed AML patients are often ineligible for 3+7 induction therapy and are being treated… read more here.
Keywords: induction therapy; newly diagnosed; ven hma; therapy ... See more keywords
Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-211261
Abstract: Background: Chromosomal rearrangements involving the KMT2A gene and mutations involving the nucleophosmin (NPM1) gene have been associated with response to menin inhibitors in multiple studies of acute myeloid leukemia (AML) patients characterized by these genetic… read more here.
Keywords: treatment; cohort; aml patients; ven hma ... See more keywords
Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-294
Abstract: Background: MECOM-rearranged (MECOM-r) AML is a rare AML subtype that is characterized by the disease-defining inv(3)(q21q26.2), t(3;3)(q21;q26.2), and other rare alterations involving 3q26.2. MECOM-r AML is an adverse-risk genetic abnormality associated with dismal outcomes in… read more here.
Keywords: treatment; ven hma; analysis; aml ... See more keywords
Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3438
Abstract: Background. NPM1 and FLT3-ITD are the most frequently observed mutations in acute myeloid leukemia (AML). However, the intensity of treatment in elderly patients (pts) with these mutations is notwelldefined. Methods. Within the Rete Ematologica Lombarda,… read more here.
Keywords: flt3 itd; fit unfit; ven hma; npm1 flt3 ... See more keywords
Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1137175
Abstract: Introduction Since allogeneic stem cell transplantation (allo-HSCT) is considered one of the curative treatments for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), hematological relapse following allo-HSCT remained a crucial concern for patients’ survival. Methods… read more here.
Keywords: ven hma; group; allo hsct; response ... See more keywords
A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15061666
Abstract: Simple Summary The introduction of venetoclax (VEN) to combination regimens has dramatically changed the paradigm of treatment for acute myeloid leukemia (AML) patients deemed unfit for intensive chemotherapy. Several researchers have reported that this regimen… read more here.
Keywords: ven hma; allo hct; newly diagnosed; therapy ... See more keywords